Figure 2.
Adverse events reported after the third BNT162b2 vaccine dose in patients with CLL (n = 168).

Adverse events reported after the third BNT162b2 vaccine dose in patients with CLL (n = 168).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal